Fig. 3From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trialsRisk of hypercalcemia, hyperphosphatemia, and elevation in the calcium-phosphorus product with paricalcitol comparing to other VDRAsBack to article page